<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Blepharitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Blepharitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Blepharitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Roni M Shtein, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah S Jacobs, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Blepharitis is a common chronic ophthalmologic condition characterized by inflammation of the eyelid margin associated with eye irritation. Other related eyelid conditions are discussed separately, as is dry eye disease, which is a frequent complication of blepharitis. (See  <a class="medical medical_review" href="/z/d/html/6898.html" rel="external">"Eyelid lesions"</a> and  <a class="medical medical_review" href="/z/d/html/6894.html" rel="external">"Dry eye disease"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">CLASSIFICATION AND PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Blepharitis is classified as either posterior or anterior. However, there tends to be considerable overlap of both types, with a predominance of posterior. The etiology and pathophysiology of blepharitis differ somewhat based on the type (posterior versus anterior).</p><p class="headingAnchor" id="H1238061837"><span class="h2">Posterior blepharitis</span><span class="headingEndMark"> — </span>Posterior blepharitis, the more common type, is characterized by inflammation of the inner portion of the eyelid at the level of the meibomian glands  (<a class="graphic graphic_picture graphicRef61924" href="/z/d/graphic/61924.html" rel="external">picture 1</a>) [<a href="#rid1">1</a>]. Meibomian glands are modified sebaceous glands, located within the tarsal plates of the eyelids, responsible for secretion of the oily layer of the tear film  (<a class="graphic graphic_figure graphicRef116369" href="/z/d/graphic/116369.html" rel="external">figure 1</a>). This oily layer prevents tear evaporation, reduces the surface tension of the tear layer, and facilitates the spread of tears [<a href="#rid2">2</a>]. It is critical for normal eye lubrication.</p><p>Hyperkeratinization of the meibomian gland ductal epithelium is an early finding in patients with posterior blepharitis [<a href="#rid3">3</a>]. Altered lipid composition in gland secretions leads to instability of the tear film [<a href="#rid4">4-10</a>]. The abnormal secretions also have a direct toxic effect on the ocular surface [<a href="#rid7">7,11</a>]. Additionally, the altered lipid composition provides an environment that promotes bacterial growth, which perpetuates the meibomian gland abnormalities. Long-term inflammation leads to gland dysfunction and fibrosis as well as damage to the eyelid and ocular surface.</p><p class="headingAnchor" id="H2858615290"><span class="h2">Anterior blepharitis</span><span class="headingEndMark"> — </span>Anterior blepharitis is characterized by inflammation at the base of the eyelashes  (<a class="graphic graphic_picture graphicRef64540" href="/z/d/graphic/64540.html" rel="external">picture 2</a>). Patients with anterior blepharitis tend to be younger than those with posterior blepharitis [<a href="#rid4">4</a>]. The pathophysiology of anterior blepharitis is not completely understood, although lid-colonizing staphylococcal bacteria appear to play a role in some cases [<a href="#rid12">12</a>]. Anterior blepharitis can be further categorized as staphylococcal or seborrheic type:</p><p class="bulletIndent1"><span class="glyph">●</span>Staphylococcal type is characterized by fibrinous scales and crust around the eyelashes caused by colonization of the eyelids by <em>Staphylococcus aureus</em> and coagulase-negative staphylococci [<a href="#rid13">13-16</a>]. Staphylococci may alter meibomian gland secretion and cause blepharitis via various mechanisms, including direct infection of the lids, production of staphylococcal exotoxin, and provoking an allergic response [<a href="#rid11">11,13-16</a>]. It is likely that a combination of these factors is responsible for the manifestations of anterior blepharitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seborrheic type is characterized by dandruff-like skin changes and greasy scales around the base of the eyelids [<a href="#rid11">11</a>].</p><p></p><p class="headingAnchor" id="H3060814349"><span class="h1">PREDISPOSING CONDITIONS</span><span class="headingEndMark"> — </span>Several conditions can predispose patients to blepharitis, although it may occur in their absence. These conditions fall into the following categories: inflammatory skin conditions, infections, irritants or allergens, and medications  (<a class="graphic graphic_table graphicRef114035" href="/z/d/graphic/114035.html" rel="external">table 1</a>). Several of these conditions are associated with both posterior and anterior blepharitis:</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic inflammatory skin conditions such as rosacea and seborrheic dermatitis may cause posterior blepharitis [<a href="#rid2">2,17,18</a>]. Other possible causes of both anterior and posterior blepharitis include contact (allergic) dermatitis, eczema, and psoriasis [<a href="#rid19">19</a>]. Blepharitis in patients with such underlying chronic dermatoses tends to be more severe, with increased redness, eyelid swelling, and discomfort. (See  <a class="medical medical_review" href="/z/d/html/13669.html" rel="external">"Seborrheic dermatitis in adolescents and adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Colonization of the eyelids by <em>S. aureus</em> and coagulase-negative staphylococci can cause anterior blepharitis as described above. Chronic colonization may also play a role in posterior blepharitis, although it is less well studied than in anterior blepharitis. The bacteria that comprise the lid and conjunctival flora in posterior blepharitis are the same as those on normal skin but present in greater numbers [<a href="#rid14">14</a>]. They include coagulase-negative staphylococci, <em>Corynebacterium</em> species, and <em>Cutibacterium acnes</em> [<a href="#rid4">4,5,15</a>]. Bacterial lipase produced by colonizing bacteria on the ocular surface may contribute to the differences in lipid composition in the tear film in patients with blepharitis [<a href="#rid2">2,13,16,20</a>].</p><p></p><p class="bulletIndent1"><em>Demodex folliculorum</em> is a parasite that has been identified in 30 percent of patients with chronic anterior blepharitis but is also found with approximately the same prevalence in asymptomatic persons [<a href="#rid21">21,22</a>]. However, it is clearly a contributing factor in some patients as evidenced by the improvement seen in response to eradicative therapy [<a href="#rid22">22</a>]. A second species, <em>Demodex brevis</em>, has been associated with posterior blepharitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contact blepharitis is an acute inflammatory reaction of the skin of the eyelids, usually occurring as a reaction to an irritant (eg, cosmetics) [<a href="#rid19">19</a>]. Factors that may provoke or exacerbate blepharitis symptoms include allergic conjunctivitis, cigarette smoking, and contact lens use [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retinoids (eg, <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>) and chemotherapeutic agents (eg, 5-fluorouracil) may predispose to posterior blepharitis [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL FINDINGS</span></p><p class="headingAnchor" id="H1303428113"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Patients with either anterior or posterior blepharitis generally present with chronic recurrent symptoms, which may vary over time, involving both eyes. These include:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Red, swollen, or itchy eyelids</p><p class="bulletIndent1"><span class="glyph">●</span>Gritty or burning sensation</p><p class="bulletIndent1"><span class="glyph">●</span>“Pink eyes” (see  <a class="medical medical_review" href="/z/d/html/6900.html" rel="external">"The red eye: Evaluation and management"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Excessive tearing (which can paradoxically be a sign of dry eye)</p><p class="bulletIndent1"><span class="glyph">●</span>Crusting or matting of eyelashes in the morning</p><p class="bulletIndent1"><span class="glyph">●</span>Flaking or scaling of the eyelid skin</p><p></p><p>Advanced cases may also have:</p><p class="bulletIndent1"><span class="glyph">●</span>Light sensitivity</p><p class="bulletIndent1"><span class="glyph">●</span>Blurred vision (transient in nature; usually improves with blinking)</p><p></p><p>Dry eye disease  (<a class="graphic graphic_picture graphicRef62824" href="/z/d/graphic/62824.html" rel="external">picture 3</a>) is a frequent complication of blepharitis, occurring in 25 to 40 percent of patients [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/6894.html" rel="external">"Dry eye disease"</a>.)</p><p>Blepharitis is more common in adults than children, and its prevalence increases with age. However, children can have dramatic episodes of anterior and/or posterior blepharitis, often characterized by more conjunctival and corneal findings than in adults [<a href="#rid25">25,26</a>].</p><p>Blepharitis related to <em>Demodex</em> infestation characteristically presents with cylindrical dandruff or “sleeves” on the eyelashes [<a href="#rid27">27</a>].</p><p>Contact (allergic) blepharitis from an irritant (eg, cosmetics) manifests with red, swollen, and itchy eyelids occurring acutely after exposure.</p><p>Symptoms of an associated chronic inflammatory skin condition may also be noted (eg, facial redness or flushing suggestive of rosacea; itchy and flaking skin involving the scalp, external ear, central face, or trunk suggestive of seborrheic dermatitis). (See  <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/13669.html" rel="external">"Seborrheic dermatitis in adolescents and adults", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H1784841514"><span class="h2">Eye examination</span><span class="headingEndMark"> — </span>The major findings of blepharitis on physical examination include pink or irritated eyelids, which may be associated with crusting.</p><p>The eyes should be examined using a slit lamp or, if a slit lamp is not available, a focused light source such as a penlight or otoscope lamp. The eyelids, conjunctivae, tear film, and cornea can be examined more closely with a slit lamp; however, it is generally not necessary to establish the diagnosis.</p><p class="headingAnchor" id="H3963512574"><span class="h3">Eyelids and eyelashes</span></p><p class="bulletIndent1"><span class="glyph">●</span>The eyelid edges in patients with blepharitis often appear pink or irritated  (<a class="graphic graphic_picture graphicRef61924" href="/z/d/graphic/61924.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef64540" href="/z/d/graphic/64540.html" rel="external">picture 2</a>). Crusting of the lashes or lid margins may also be visible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with anterior blepharitis typically have adherent material around their eyelashes. In the seborrheic variant of anterior blepharitis, there are often greasy-appearing flakes; whereas in the staphylococcal variant, a hard cylindrical crust develops around the eyelash (called a "collarette") [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In posterior blepharitis, it is common to see enlargement of the meibomian gland openings and plugging with thickened, waxy secretions appearing as white or yellow mounds at the gland opening  (<a class="graphic graphic_picture graphicRef53663" href="/z/d/graphic/53663.html" rel="external">picture 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of cylindrical dandruff or “sleeves” on the eyelashes can indicate <em>Demodex</em> infection. (See <a class="local">'Ancillary testing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic inflammation can be detected on examination:</p><p></p><p class="bulletIndent1">The eyelashes should be carefully evaluated as chronic inflammation can lead to trichiasis (misdirected eyelashes), madarosis (loss of lashes), poliosis (loss of pigmentation of lashes), or distichiasis (abnormal growth of eyelashes from meibomian gland orifices). Chronic inflammation can lead to structural changes resulting in entropion (inward turning of eyelid)  (<a class="graphic graphic_picture graphicRef63579" href="/z/d/graphic/63579.html" rel="external">picture 5</a>) or ectropion (outward turning of eyelid)  (<a class="graphic graphic_picture graphicRef72737" href="/z/d/graphic/72737.html" rel="external">picture 6</a>).</p><p></p><p class="bulletIndent1">Other findings that are suggestive of chronic inflammation include neovascularization and dilation of blood vessels of the lid margins, thickening of the lid skin, irregularity of the lid contour, and ulcerations along the lid margin. These findings can be observed with a penlight but are more easily appreciated with slit-lamp magnification.</p><p></p><p class="headingAnchor" id="H3148840291"><span class="h3">Conjunctivae</span><span class="headingEndMark"> — </span>Diffuse conjunctival injection is a common but nonspecific finding in patients with blepharitis. Injection may be more prominent on the palpebral conjunctiva [<a href="#rid2">2</a>]. Blepharitis can also be associated with a papillary conjunctival reaction  (<a class="graphic graphic_picture graphicRef76072" href="/z/d/graphic/76072.html" rel="external">picture 7</a>), which appears as raised but flat-topped nodules with central vessels.</p><p class="headingAnchor" id="H930708393"><span class="h3">Tear film</span><span class="headingEndMark"> — </span>Tear film irregularities are suggested by the presence of debris and/or a foamy appearance on slit-lamp examination. Tear film stability can be formally assessed by measuring the tear break-up time or tear evaporation rate.</p><p>Tear break-up time is performed by examining the tear film with a slit lamp using blue light after instilling <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> stain in the eye. A healthy tear film appears as a green sheen that remains stable for at least 10 seconds. An abnormal tear film becomes irregular or breaks up in less than 10 seconds.</p><p>The tear evaporation rate, which is more often used in research than clinical practice, also assesses the tear film stability and is measured with advanced imaging instruments that use interferometry.</p><p class="headingAnchor" id="H1494375162"><span class="h3">Cornea</span><span class="headingEndMark"> — </span>Corneal abnormalities are infrequent complications of blepharitis. They are best seen with a slit lamp and may include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Erosions – Corneal erosions are most commonly found where the inflamed lid margins cross the cornea at the 2, 4, 8, and 10 o'clock positions. Punctate epithelial erosions may appear in the inferior third of the cornea [<a href="#rid11">11</a>]. Similar erosions may be associated with dry eyes, but in that condition they are more commonly distributed throughout the interpalpebral space. (See  <a class="medical medical_review" href="/z/d/html/6894.html" rel="external">"Dry eye disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infiltrates – Marginal corneal infiltrates may occur as a hypersensitivity reaction to staphylococcal antigens [<a href="#rid29">29</a>]. These appear as an area of superficial whitening near the limbus (border of the cornea and sclera). An area of clear cornea between the limbus and the infiltrate is characteristic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nodules – Corneal nodules (phlyctenules) develop near the limbus and then spread onto the cornea, carrying behind them a leash of vessels. They are considered to be another form of hypersensitivity reaction to staphylococcal antigens [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ulcers – Rarely, corneal marginal ulcers can develop in the setting of blepharitis. These must be recognized and treated appropriately to avoid progression to corneal perforation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Scarring – Chronic irritation and recurrent corneal infiltrates can lead to scarring and development of a superficial corneal pannus (“pseudo-pterygium”)  (<a class="graphic graphic_picture graphicRef81259" href="/z/d/graphic/81259.html" rel="external">picture 8</a>).</p><p></p><p class="headingAnchor" id="H2825464887"><span class="h2">Ancillary testing</span><span class="headingEndMark"> — </span>Ancillary testing (eg, bacterial culture, microscopic examination of the eyelash, imaging techniques [meibography]) is not necessary to establish the diagnosis of blepharitis but may have a role in some clinical settings. Culture of the eyelid margins has limited utility because of the difficulty in distinguishing bacterial infection from colonization. However, it may be useful in patients with severe blepharitis and in those who are not responding to empiric therapy [<a href="#rid23">23</a>].</p><p>Epilation of the eyelashes for microscopic examination to detect <em>Demodex</em> mites is warranted when the clinical presentation (eg, presence of cylindrical dandruff or “sleeves” on the eyelashes) is suggestive of this diagnosis or when there is severe or refractory blepharitis [<a href="#rid23">23</a>]. It is performed by the ophthalmologist placing the eyelashes on a glass slide and examining under a cover slip after a drop of <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> has been added.</p><p>Techniques of imaging and measuring the meibomian gland size and function, ocular surface, and tear film dynamics are available and can provide more objective measures of the eyelids and tear function in patients with blepharitis [<a href="#rid31">31-33</a>]. However, these are not routinely used in clinical practice.</p><p class="headingAnchor" id="H9"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Blepharitis is a clinical diagnosis based on characteristic findings of redness and irritation of the eyelid margin associated with crusting or flakes on the lashes or lid margins  (<a class="graphic graphic_picture graphicRef61924" href="/z/d/graphic/61924.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef64540" href="/z/d/graphic/64540.html" rel="external">picture 2</a>). It is a bilateral condition but can have asymmetric findings. Slit lamp allows for more detailed examination of the meibomian glands, which can help distinguish between posterior and anterior blepharitis. However, it is generally not necessary to make the diagnosis. (See <a class="local">'Eye examination'</a> above.)</p><p>The diagnosis of blepharitis can be made by the primary care practitioner in most instances. If the diagnosis is unclear based upon clinical findings, referral to an ophthalmologist for slit-lamp examination (if not available in primary care site) is advised. (See <a class="local">'Indications for referral'</a> below.)</p><p class="headingAnchor" id="H1678461383"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Blepharitis can be distinguished from other conditions associated with redness and discomfort of the eyelid based upon the history and physical examination:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conjunctivitis</strong> – Conjunctivitis, which may be infectious, allergic, or toxic in etiology, is characterized by erythema of eye (rather than eyelids) and the presence of clear or purulent discharge. Vision should be normal, and there should be no evidence of other causes of “red eye” (eg, keratitis, iritis). (See  <a class="medical medical_review" href="/z/d/html/6907.html" rel="external">"Conjunctivitis", section on 'Evaluation and diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hordeolum</strong> – A hordeolum (stye) is an acute inflammation of an oil gland of the eyelid that presents as a red tender bump on the eyelid  (<a class="graphic graphic_picture graphicRef79059" href="/z/d/graphic/79059.html" rel="external">picture 9</a>). It can be associated with blepharitis because abnormal oily secretions block lid glands that may become secondarily infected. Treatment involves application of warm, moist compresses four times a day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chalazion</strong> – A chalazion is a firm, non-tender bump on the eyelid that represents a chronic sterile inflammation of an oil gland of the eyelid  (<a class="graphic graphic_picture graphicRef62030" href="/z/d/graphic/62030.html" rel="external">picture 10</a>). It results from a granulomatous inflammatory reaction to the lipid content of the blocked lid gland  (<a class="graphic graphic_figure graphicRef139242" href="/z/d/graphic/139242.html" rel="external">figure 2</a>) [<a href="#rid2">2</a>]. Treatment involves application of warm, moist compresses four times a day. If the symptoms do not respond after several weeks, incision and curettage or intralesional glucocorticoid injection can be performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eyelid malignancy</strong> – A malignant tumor of the lid skin (sebaceous carcinoma) should be suspected in a patient with persistent unilateral eyelid inflammation  (<a class="graphic graphic_picture graphicRef70403" href="/z/d/graphic/70403.html" rel="external">picture 11</a>) [<a href="#rid34">34-37</a>]. Other symptoms of malignancy include a nodular mass, ulceration, extensive scarring, or conjunctival nodules with inflammation [<a href="#rid23">23</a>]. Eyelid malignancy should be considered in patients with unilateral blepharitis that does not respond to treatment. The diagnosis it is confirmed with biopsy. (See  <a class="medical medical_review" href="/z/d/html/6898.html" rel="external">"Eyelid lesions", section on 'Sebaceous carcinoma'</a>.)</p><p></p><p class="headingAnchor" id="H1010257096"><span class="h1">INDICATIONS FOR REFERRAL</span><span class="headingEndMark"> — </span>Most patients with blepharitis can be diagnosed and managed by the primary care practitioner. However, referral to an ophthalmologist is warranted if any of the following are present [<a href="#rid23">23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe eye redness, pain, or light sensitivity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impaired vision.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Corneal abnormalities (eg, erosions, ulcers, scarring).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Uncertain diagnosis or concern for malignancy. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspicion of <em>Demodex </em>infection. (See <a class="local">'Ancillary testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe or refractory symptoms with poor response to standard management. We define severe symptoms as those affecting vision or quality of life. (See <a class="local">'Severe or continuing symptoms'</a> below.)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1261336886"><span class="h2">General approach</span><span class="headingEndMark"> — </span>Patients should be counseled that blepharitis is a chronic condition and many people will require long-term care. Good lid hygiene is the mainstay of treatment for all forms of blepharitis. The goal is to alleviate symptoms and to develop a maintenance regimen to prevent or minimize future exacerbations. Our management approach is based on clinical experience, limited clinical trial and observational data, and consensus expert opinion [<a href="#rid38">38,39</a>]. Our approach is presented in the algorithm  (<a class="graphic graphic_algorithm graphicRef131396" href="/z/d/graphic/131396.html" rel="external">algorithm 1</a>).</p><p>All patients should be advised to eliminate or limit potential triggers or exacerbating factors (eg, allergens, cigarette smoking). Contact lenses may continue to be worn if comfortable. Some wearers may benefit from refitting of lenses or the use of a different lens material.</p><p>The management of contact (allergic) blepharitis consists of eliminating use of the offending agent (eg, cosmetics). Patients who use cosmetics should be vigilant about removing their makeup at night, cleaning applicators, and avoiding old or expired products.</p><p class="headingAnchor" id="H3878335003"><span class="h2">Mild to moderate symptoms</span><span class="headingEndMark"> — </span>For patients with mild to moderate symptoms, management consists of warm compresses, lid massage, lid washing, and <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">artificial tears</a>. These patients can generally be managed by the primary care practitioner.</p><p>Blepharitis is a chronic condition that requires long-term management. The intensity level of treatment varies based on patient symptoms. Most patients with mild to moderate symptoms respond well to the basic interventions described below. Although it may vary based on the severity of symptoms, in general, these measures should be trialed for approximately six weeks before moving on to other treatments. The efficacy of lid hygiene measures for symptom relief in patients with chronic posterior or anterior blepharitis has been demonstrated in several small clinical trials [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H22"><span class="h3">Warm compresses</span><span class="headingEndMark"> — </span>Application of heat to the lids and meibomian glands can liquefy the abnormal solidified secretions by heating them above their melting point. Heat may also promote increased circulation in the meibomian glands and thereby increase the quantity of secretions.</p><p>Patients should be advised to soak a wash cloth in warm (not hot) water and place it over the eyes. As the wash cloth cools, it should be rewarmed and replaced for a total of 5 to 10 minutes of soaking time. Warm compresses should be applied two to four times a day as long as the patient has symptoms and at a decreased frequency in the maintenance phase. Numerous eyelid-warming devices are commercially available [<a href="#rid40">40,41</a>]. Such devices are unlikely to be more or less efficacious than using a warm wash cloth, but some patients may prefer them.</p><p class="headingAnchor" id="H23"><span class="h3">Lid massage</span><span class="headingEndMark"> — </span>Lid massage may help empty the meibomian glands and improve secretion, especially in patients with posterior blepharitis and meibomian gland inspissation. Lid massage should be performed immediately following application of a warm compress, a few times a day. Either the wash cloth that was used for the compress or a clean fingertip should be used to gently massage the edge of the eyelid towards the eye with a gentle circular motion.</p><p class="headingAnchor" id="H24"><span class="h3">Lid washing</span><span class="headingEndMark"> — </span>Patients with accumulation of debris on the eyelashes may benefit from gentle washing of the eyelid margins following the use of a warm compress. Either warm water or very dilute baby shampoo can be placed on a clean wash cloth, gauze pad, or cotton swab. The patient should then be advised to gently clean along the lashes and lid margin to remove the accumulated material with care to avoid contacting the ocular surface. If shampoo is used, thorough rinsing is recommended. Vigorous washing should be avoided, as it may cause more irritation. Commercially available eyelid scrub solutions are safe and effective and may be preferred for convenience and ease of use [<a href="#rid42">42,43</a>].</p><p class="headingAnchor" id="H1053971314"><span class="h3">Artificial tears</span><span class="headingEndMark"> — </span>Patients often need to use supplemental artificial tear eye drops to treat the dryness associated with blepharitis (see  <a class="medical medical_review" href="/z/d/html/6894.html" rel="external">"Dry eye disease"</a>). Ocular lubrication may also improve contact lens tolerance in patients with blepharitis.</p><p class="headingAnchor" id="H2147158613"><span class="h3">Ineffective therapies</span><span class="headingEndMark"> — </span>We do not routinely suggest omega-3 fatty acid supplementation for patients with blepharitis. Clinical trials of oral omega-3 fatty acid supplementation for treatment of meibomian gland dysfunction, posterior blepharitis, and dry eye have shown mixed results [<a href="#rid44">44-50</a>]. Most studies have been small and have evaluated surrogate outcomes such as tear break-up time. In the largest trial, there was no apparent benefit [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H4268402316"><span class="h2">Severe or continuing symptoms</span></p><p class="headingAnchor" id="H915218731"><span class="h3">Overview</span><span class="headingEndMark"> — </span>For patients who do not respond to the symptomatic measures described above and for those with severe symptoms (affecting vision or quality of life), we suggest initiating treatment with topical or oral antibiotic therapy in addition to continuing symptomatic measures. Because of the potential for systemic side effects with oral drugs, topical therapy is usually tried first. Patients with severe or refractory symptoms should be referred to an ophthalmologist for confirmation of the diagnosis and for monitoring during treatment. Other treatment options include topical glucocorticoids and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (only to be prescribed by or in consultation with an ophthalmologist).</p><p class="headingAnchor" id="H26"><span class="h3">Topical antibiotics</span><span class="headingEndMark"> — </span>We suggest topical antibiotic therapy for patients who do not respond to the symptomatic measures described above.</p><p>Topical ophthalmic antibiotic ointments (eg, <a class="drug drug_general" data-topicid="9052" href="/z/d/drug information/9052.html" rel="external">bacitracin</a>, <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>) may improve symptoms by reducing the bacterial load of the lashes and conjunctivae. These agents tend to be more effective in anterior blepharitis when the inflammation is more localized to the lash follicles than the meibomian glands; however, as previously described, there is considerable overlap between anterior and posterior blepharitis, and patients with posterior blepharitis may also respond. Both bacitracin and erythromycin have broad spectrum antimicrobial activity and are generally well tolerated. Antibiotic ointment is placed directly onto the lid margin once daily at bedtime for two weeks. Once symptoms improve, treatment can be stopped, but lid hygiene measures should be continued. (See <a class="local">'Lid washing'</a> above.)</p><p>Topical <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> ophthalmic solution 1% is an alternative agent particularly for patients with posterior blepharitis. Dosing is one drop twice daily for 10 to 14 days. Azithromycin has been shown to improve meibomian gland secretions and to decrease eyelid redness compared with warm compresses alone [<a href="#rid51">51</a>].</p><p>A systematic review of randomized controlled trials and quasi-randomized controlled trials of patients with chronic posterior or anterior blepharitis found that topical antibiotics were effective in providing symptomatic relief and in eradicating bacteria at the lid margin in patients with anterior blepharitis [<a href="#rid38">38</a>]. Additional studies have suggested that antibiotics may have a direct effect on improving meibomian gland function [<a href="#rid52">52,53</a>].</p><p class="headingAnchor" id="H27"><span class="h3">Oral antibiotics after trial of topical antibiotics</span><span class="headingEndMark"> — </span>Oral antibiotics (eg, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>), are generally reserved for patients with chronic moderate to severe blepharitis that have an inadequate response to topical antibiotic therapy. Treatment is initiated with doxycycline 100 mg or tetracycline 1000 mg daily in divided doses and tapered after improvement (usually two to four weeks) to doxycycline 50 mg or tetracycline 250 to 500 mg once a day. An alternative regimen is azithromycin 500 mg on day 1, followed by 250 mg for four more days.</p><p>Evidence supporting the use of oral antibiotics to treat blepharitis is based on mainly observational studies. In a systematic review of eight studies (one randomized trial and seven observational studies) evaluating antibiotic therapy for treatment of posterior blepharitis, all of the included studies documented improvements in ocular surface disease [<a href="#rid54">54</a>]. Most of the studies were small (five included ≤20 patients), and each used a different treatment regimen, including <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, or <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>. Another systematic review found that the evidence for efficacy of oral antibiotics was inconclusive [<a href="#rid38">38</a>].</p><p>Tetracyclines effectively reduce the load of colonizing lid and conjunctival bacteria [<a href="#rid55">55</a>]. They also decrease keratinization and bacterial lipase production [<a href="#rid56">56-58</a>]. Tetracyclines may be especially useful in patients with ocular manifestations of rosacea [<a href="#rid59">59</a>]. In addition, they are associated with reduction of matrix metalloproteinase activity that may play a role in chronic blepharitis [<a href="#rid60">60</a>].</p><p>Tetracyclines may cause photosensitization, gastrointestinal side effects, and pseudotumor cerebri, as well as interfere with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> and the effectiveness of oral contraceptives. They are contraindicated in pregnant or nursing women and in children under 12 years of age. <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> or other macrolides should be used in these settings. Nausea and other gastrointestinal side effects are common with azithromycin.</p><p class="headingAnchor" id="H1701201592"><span class="h2">Refractory symptoms</span><span class="headingEndMark"> — </span>Patients with refractory symptoms should be referred to an ophthalmologist.</p><p class="headingAnchor" id="H28"><span class="h3">Topical glucocorticoids</span><span class="headingEndMark"> — </span>Topical glucocorticoid eyedrops, gels, and ointments are generally reserved for patients with blepharitis that is unresponsive to other therapies [<a href="#rid23">23</a>]. Low-potency agents such as <a class="drug drug_general" data-topicid="9867" href="/z/d/drug information/9867.html" rel="external">rimexolone</a>, <a class="drug drug_general" data-topicid="10116" href="/z/d/drug information/10116.html" rel="external">loteprednol</a> etabonate, and <a class="drug drug_general" data-topicid="8463" href="/z/d/drug information/8463.html" rel="external">fluorometholone</a> are preferred to reduce the risk for adverse effects. Topical glucocorticoids should only be prescribed by or in consultation with an ophthalmologist. Treatment should be limited to two to three weeks to reduce the risk for cataract formation or glaucoma. If topical glucocorticoids are prescribed, patients should be reevaluated in a few weeks to measure intraocular pressure and to determine response to treatment.</p><p>Small clinical trials demonstrated short-term improvements in symptom scores, clinical findings (eg, lid margin injection, tear break-up time, meibomian gland expressibility), and tear cytokine levels in patients treated with topical glucocorticoids compared with controls [<a href="#rid61">61,62</a>]. A systematic review concluded that the evidence for the effectiveness of topical glucocorticoids in blepharitis is inconclusive [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H29"><span class="h3">Topical cyclosporine</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> should be reserved for patients with blepharitis who do not respond to standard therapies and should be prescribed by an ophthalmologist [<a href="#rid23">23</a>]. It is available as 0.05% eye drops.</p><p>Several small prospective studies have demonstrated improvements in objective measures of meibomian gland dysfunction (eg, lid margin injection, tear break-up time, meibomian gland expressibility) in patients treated with topical <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> compared with controls; only one study demonstrated improvement in symptoms [<a href="#rid63">63-65</a>].</p><p>The choice between topical glucocorticoids and topical <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> is based on clinician and patient preference. In our experience, topical glucocorticoids tend to be more effective than topical cyclosporine but have greater potential for adverse effects.</p><p>Topical <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> is approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for treatment of dry eyes, but its use in treatment of blepharitis in the absence of dry eye disease is “off-label.” The use of topical cyclosporine in management of dry eyes is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6894.html" rel="external">"Dry eye disease", section on 'Topical cyclosporine'</a>.)</p><p>“Off-label” use of topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> has also been described. Limited evidence suggests that tacrolimus can improve symptoms and ocular surface status in patients with refractory posterior blepharitis [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H1136994067"><span class="h2">Demodex infestation</span><span class="headingEndMark"> — </span>Blepharitis associated with <em>Demodex</em> species infestation can be treated either with topical tea tree oil eyelid scrubs (administered weekly for six weeks), tea tree shampoo (applied daily for six weeks), <a class="drug drug_general" data-topicid="142079" href="/z/d/drug information/142079.html" rel="external">lotilaner</a> 0.25% ophthalmic solution (one drop twice daily for six weeks), oral <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> (200 mcg/kg in a single dose and repeated once in one week), or topical ivermectin 1% cream ("off-label", with instructions not to allow the produce to get into the patient’s eyes) [<a href="#rid23">23,67-70</a>]. The choice of treatment is based on patient preference after shared decision making and may be influenced by cost and availability of treatments. <em>Demodex</em> infestation is suggested by the presence of cylindrical dandruff or "sleeves" on the eyelashes or by severe or refractory blepharitis. The diagnosis is confirmed by the presence of <em>Demodex</em> mites on microscopic examination. (See <a class="local">'Ancillary testing'</a> above.)</p><p class="headingAnchor" id="H7508989"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83063.html" rel="external">"Patient education: Blepharitis (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16336.html" rel="external">"Patient education: Stye (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/83738.html" rel="external">"Patient education: Chalazion (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H37"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification and pathophysiology</strong> – Blepharitis is a common chronic ophthalmologic condition characterized by inflammation of the eyelids associated with eye irritation. The etiology and pathophysiology of blepharitis differ somewhat based on the type (posterior versus anterior)  (<a class="graphic graphic_table graphicRef114035" href="/z/d/graphic/114035.html" rel="external">table 1</a>). However, there is considerable overlap between these categories.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Posterior blepharitis</strong> – Posterior blepharitis, the more common condition, is characterized by inflammation of the inner portion of the eyelid at the level of the meibomian glands (modified sebaceous glands located within the tarsal plates of the eyelids), which are dysfunctional  (<a class="graphic graphic_picture graphicRef61924" href="/z/d/graphic/61924.html" rel="external">picture 1</a>). It can be associated with rosacea or seborrheic dermatitis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anterior blepharitis</strong> – Anterior blepharitis is characterized by inflammation at the base of the eyelashes  (<a class="graphic graphic_picture graphicRef64540" href="/z/d/graphic/64540.html" rel="external">picture 2</a>). It can be associated with staphylococcal colonization or seborrhea. (See <a class="local">'Classification and pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predisposing conditions</strong> – Several conditions can predispose patients to blepharitis, although it may occur in their absence. These conditions fall into the following categories: inflammatory skin conditions, infections, irritants or allergens, and medications  (<a class="graphic graphic_table graphicRef114035" href="/z/d/graphic/114035.html" rel="external">table 1</a>). Several of these conditions are associated with both posterior and anterior blepharitis. (See <a class="local">'Predisposing conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients with blepharitis generally present with symptoms of chronic irritation involving both eyes. These include red, swollen, or itchy eyelids; gritty or burning sensation; “pink eyes”; excessive tearing (which can paradoxically be a sign of dry eye); crusting or matting of eyelashes in the morning; flaking or scaling of the eyelid skin; light sensitivity; and blurred vision (transient in nature, usually improves with blinking). The eyelid edges often appear pink or irritated. Crusting of the lashes or lid margins may also be visible. (See <a class="local">'Clinical findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Blepharitis is a clinical diagnosis based on characteristic findings of redness and irritation of the eyelid margin associated with crusting or flakes on the lashes or lid margins  (<a class="graphic graphic_picture graphicRef61924" href="/z/d/graphic/61924.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef64540" href="/z/d/graphic/64540.html" rel="external">picture 2</a>). Slit lamp allows for more detailed examination of the meibomian glands, which can help distinguish between posterior and anterior blepharitis. However, it is generally not necessary to make the distinction. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis for blepharitis includes other conditions associated with redness and discomfort of the eyelid such as conjunctivitis, hordeolum (stye), chalazion, and eyelid malignancy. Blepharitis is distinguished from these conditions based upon the history and physical examination. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for ophthalmologic referral</strong> – Indications for referral to an ophthalmologist include severe eye redness or pain, light sensitivity, impaired vision, corneal abnormalities (eg, erosions, ulcers, scarring), uncertain diagnosis or concern for malignancy, <em>Demodex</em> infection, or severe or refractory symptoms. (See <a class="local">'Indications for referral'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General treatment measures</strong> – Good lid hygiene is the mainstay of treatment for all forms of blepharitis. In addition, patients should be advised to eliminate or limit potential triggers or exacerbating factors (eg, allergens, cigarette smoking, contact lenses). The goal is to alleviate symptoms and to develop a maintenance regimen to prevent or minimize future exacerbations. Blepharitis is a chronic condition that requires long-term management. The intensity level of treatment varies based on patient symptoms (see <a class="local">'Management'</a> above). Our approach is presented in the algorithm  (<a class="graphic graphic_algorithm graphicRef131396" href="/z/d/graphic/131396.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment for mild or moderate symptoms</strong> – All patients with blepharitis should be advised to use warm compresses, lid massage, and lid washing. This treatment is typically sufficient in patients with mild to moderate symptoms. In addition, patients may benefit from supplemental artificial tear eye drops to treat the dryness associated with blepharitis. Patients whose symptoms do not respond to these measures should be treated with topical antibiotics. (See <a class="local">'Mild to moderate symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment for more severe symptoms or continuing symptoms</strong> – Patients who present with more severe symptoms or who do not respond to the symptomatic measures described above should generally be managed by an ophthalmologist. In such patients, we suggest addition of topical antibiotic therapy to symptomatic measures (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Although oral antibiotic therapy is an alternative, topical therapy is usually tried first because of the potential for systemic side effects with oral drugs.</p><p></p><p class="bulletIndent2">For most patients, antibiotic ointment (eg, <a class="drug drug_general" data-topicid="9052" href="/z/d/drug information/9052.html" rel="external">bacitracin</a>, <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>) is placed directly onto the lid margin once daily at bedtime. Topical <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> ophthalmic solution 1% is an alternative agent for patients with predominantly posterior blepharitis. Dosing is one drop twice daily for 10 to 14 days. Once symptoms improve (generally one to two weeks), treatment can be stopped, but lid hygiene measures should be continued.</p><p></p><p class="bulletIndent2">In patients whose response to topical therapy is inadequate, we suggest switching to oral antibiotic therapy rather than using glucocorticoids or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a>, <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, or <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> are typically used. (See <a class="local">'Topical antibiotics'</a> above and <a class="local">'Oral antibiotics after trial of topical antibiotics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of refractory symptoms</strong> – Patients with symptoms refractory to antibiotic therapy can be treated with topical glucocorticoids and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>. These agents should only be prescribed by or in consultation with an ophthalmologist. (See <a class="local">'Severe or continuing symptoms'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci 2011; 52:1922.</a></li><li><a class="nounderline abstract_t">Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol 1996; 40:343.</a></li><li><a class="nounderline abstract_t">Gutgesell VJ, Stern GA, Hood CI. Histopathology of meibomian gland dysfunction. Am J Ophthalmol 1982; 94:383.</a></li><li><a class="nounderline abstract_t">McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology 1982; 89:1173.</a></li><li><a class="nounderline abstract_t">McCulley JP, Dougherty JM. Blepharitis associated with acne rosacea and seborrheic dermatitis. Int Ophthalmol Clin 1985; 25:159.</a></li><li><a class="nounderline abstract_t">Shine WE, McCulley JP. Meibomian gland triglyceride fatty acid differences in chronic blepharitis patients. Cornea 1996; 15:340.</a></li><li><a class="nounderline abstract_t">Dougherty JM, McCulley JP. Analysis of the free fatty acid component of meibomian secretions in chronic blepharitis. Invest Ophthalmol Vis Sci 1986; 27:52.</a></li><li><a class="nounderline abstract_t">Shine WE, McCulley JP. Polar lipids in human meibomian gland secretions. Curr Eye Res 2003; 26:89.</a></li><li><a class="nounderline abstract_t">Shine WE, McCulley JP. Meibomianitis: polar lipid abnormalities. Cornea 2004; 23:781.</a></li><li><a class="nounderline abstract_t">Baudouin C. The pathology of dry eye. Surv Ophthalmol 2001; 45 Suppl 2:S211.</a></li><li><a class="nounderline abstract_t">Smith RE, Flowers CW Jr. Chronic blepharitis: a review. CLAO J 1995; 21:200.</a></li><li><a class="nounderline abstract_t">Thygeson, P. The etiology and treatment of blepharitis: a study in military personnel. Arch Ophthalmol 1946; 98:191.</a></li><li><a class="nounderline abstract_t">Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. Br J Ophthalmol 1984; 68:524.</a></li><li><a class="nounderline abstract_t">McCulley JP, Dougherty JM. Bacterial aspects of chronic blepharitis. Trans Ophthalmol Soc U K 1986; 105 ( Pt 3):314.</a></li><li><a class="nounderline abstract_t">Groden LR, Murphy B, Rodnite J, Genvert GI. Lid flora in blepharitis. Cornea 1991; 10:50.</a></li><li><a class="nounderline abstract_t">Dougherty JM, McCulley JP. Bacterial lipases and chronic blepharitis. Invest Ophthalmol Vis Sci 1986; 27:486.</a></li><li><a class="nounderline abstract_t">Burton JL, Pye RJ, Meyrick G, Shuster S. The sebum excretion rate in rosacea. Br J Dermatol 1975; 92:541.</a></li><li><a class="nounderline abstract_t">Karalezli A, Borazan M, Dursun R, et al. Impression cytology and ocular surface characteristics in patients with seborrhoeic dermatitis. Acta Ophthalmol 2011; 89:e137.</a></li><li><a class="nounderline abstract_t">Raskin EM, Speaker MG, Laibson PR. Blepharitis. Infect Dis Clin North Am 1992; 6:777.</a></li><li><a class="nounderline abstract_t">McCulley JP, Shine WE. The lipid layer of tears: dependent on meibomian gland function. Exp Eye Res 2004; 78:361.</a></li><li><a class="nounderline abstract_t">Roth AM. Demodex folliculorum in hair follicles of eyelid skin. Ann Ophthalmol 1979; 11:37.</a></li><li><a class="nounderline abstract_t">Kemal M, Sümer Z, Toker MI, et al. The Prevalence of Demodex folliculorum in blepharitis patients and the normal population. Ophthalmic Epidemiol 2005; 12:287.</a></li><li class="breakAll">American Academy of Ophthalmology. Blepharitis: Preferred Practice Pattern. Available at: https://www.aao.org/preferred-practice-pattern/blepharitis-ppp--2013 (Accessed on June 01, 2017).</li><li><a class="nounderline abstract_t">Bowman RW, Dougherty JM, McCulley JP. Chronic blepharitis and dry eyes. Int Ophthalmol Clin 1987; 27:27.</a></li><li><a class="nounderline abstract_t">Viswalingam M, Rauz S, Morlet N, Dart JK. Blepharokeratoconjunctivitis in children: diagnosis and treatment. Br J Ophthalmol 2005; 89:400.</a></li><li><a class="nounderline abstract_t">Doan S, Gabison EE, Nghiem-Buffet S, et al. Long-term visual outcome of childhood blepharokeratoconjunctivitis. Am J Ophthalmol 2007; 143:528.</a></li><li><a class="nounderline abstract_t">Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci 2005; 46:3089.</a></li><li><a class="nounderline abstract_t">Gilbard JP. Dry eye, blepharitis and chronic eye irritation: divide and conquer. J Ophthalmic Nurs Technol 1999; 18:109.</a></li><li><a class="nounderline abstract_t">Smolin G, Okumoto M. Staphylococcal blepharitis. Arch Ophthalmol 1977; 95:812.</a></li><li><a class="nounderline abstract_t">Mondino BJ. Inflammatory diseases of the peripheral cornea. Ophthalmology 1988; 95:463.</a></li><li><a class="nounderline abstract_t">Arita R, Suehiro J, Haraguchi T, et al. Objective image analysis of the meibomian gland area. Br J Ophthalmol 2014; 98:746.</a></li><li><a class="nounderline abstract_t">Liang Q, Pan Z, Zhou M, et al. Evaluation of Optical Coherence Tomography Meibography in Patients With Obstructive Meibomian Gland Dysfunction. Cornea 2015; 34:1193.</a></li><li><a class="nounderline abstract_t">Abdelfattah NS, Dastiridou A, Sadda SR, Lee OL. Noninvasive Imaging of Tear Film Dynamics in Eyes With Ocular Surface Disease. Cornea 2015; 34 Suppl 10:S48.</a></li><li><a class="nounderline abstract_t">Brownstein S, Codere F, Jackson WB. Masquerade syndrome. Ophthalmology 1980; 87:259.</a></li><li><a class="nounderline abstract_t">Akpek EK, Polcharoen W, Chan R, Foster CS. Ocular surface neoplasia masquerading as chronic blepharoconjunctivitis. Cornea 1999; 18:282.</a></li><li><a class="nounderline abstract_t">Kass LG, Hornblass A. Sebaceous carcinoma of the ocular adnexa. Surv Ophthalmol 1989; 33:477.</a></li><li><a class="nounderline abstract_t">Shields JA, Demirci H, Marr BP, et al. Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology 2004; 111:2151.</a></li><li><a class="nounderline abstract_t">Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis. Cochrane Database Syst Rev 2012; :CD005556.</a></li><li class="breakAll">American Academy of Ophthalmology. Blepharitis PPP-2018. Available at: https://www.aao.org/preferred-practice-pattern/blepharitis-ppp-2018 (Accessed on May 17, 2022).</li><li><a class="nounderline abstract_t">Arita R, Morishige N, Shirakawa R, et al. Effects of Eyelid Warming Devices on Tear Film Parameters in Normal Subjects and Patients with Meibomian Gland Dysfunction. Ocul Surf 2015; 13:321.</a></li><li><a class="nounderline abstract_t">Wang MT, Gokul A, Craig JP. Temperature profiles of patient-applied eyelid warming therapies. Cont Lens Anterior Eye 2015; 38:430.</a></li><li><a class="nounderline abstract_t">Polack FM, Goodman DF. Experience with a new detergent lid scrub in the management of chronic blepharitis. Arch Ophthalmol 1988; 106:719.</a></li><li><a class="nounderline abstract_t">Key JE. A comparative study of eyelid cleaning regimens in chronic blepharitis. CLAO J 1996; 22:209.</a></li><li><a class="nounderline abstract_t">Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc 2008; 106:336.</a></li><li><a class="nounderline abstract_t">Oleñik A, Jiménez-Alfaro I, Alejandre-Alba N, Mahillo-Fernández I. A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction. Clin Interv Aging 2013; 8:1133.</a></li><li><a class="nounderline abstract_t">Wojtowicz JC, Butovich I, Uchiyama E, et al. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea 2011; 30:308.</a></li><li><a class="nounderline abstract_t">Dry Eye Assessment and Management Study Research Group, Asbell PA, Maguire MG, et al. n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. N Engl J Med 2018; 378:1681.</a></li><li><a class="nounderline abstract_t">Bhargava R, Kumar P. Oral omega-3 fatty acid treatment for dry eye in contact lens wearers. Cornea 2015; 34:413.</a></li><li><a class="nounderline abstract_t">Kangari H, Eftekhari MH, Sardari S, et al. Short-term consumption of oral omega-3 and dry eye syndrome. Ophthalmology 2013; 120:2191.</a></li><li><a class="nounderline abstract_t">Deinema LA, Vingrys AJ, Wong CY, et al. A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease. Ophthalmology 2017; 124:43.</a></li><li><a class="nounderline abstract_t">Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther 2008; 25:858.</a></li><li><a class="nounderline abstract_t">Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea 2013; 32:44.</a></li><li><a class="nounderline abstract_t">Liu Y, Kam WR, Ding J, Sullivan DA. Effect of azithromycin on lipid accumulation in immortalized human meibomian gland epithelial cells. JAMA Ophthalmol 2014; 132:226.</a></li><li><a class="nounderline abstract_t">Wladis EJ, Bradley EA, Bilyk JR, et al. Oral Antibiotics for Meibomian Gland-Related Ocular Surface Disease: A Report by the American Academy of Ophthalmology. Ophthalmology 2016; 123:492.</a></li><li><a class="nounderline abstract_t">Ta CN, Shine WE, McCulley JP, et al. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea 2003; 22:545.</a></li><li><a class="nounderline abstract_t">Cullen SI, Crounse RG. Cutaneous pharmacology of the tetracyclines. J Invest Dermatol 1965; 45:263.</a></li><li><a class="nounderline abstract_t">Mates A. Inhibition by tetracycline in the occurrence of extracellular lipase from Staphylococcus aureus. Microbios 1973; 7:25.</a></li><li><a class="nounderline abstract_t">Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci 1991; 32:2970.</a></li><li><a class="nounderline abstract_t">Frucht-Pery J, Sagi E, Hemo I, Ever-Hadani P. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol 1993; 116:88.</a></li><li><a class="nounderline abstract_t">Iovieno A, Lambiase A, Micera A, et al. In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. Eur J Ophthalmol 2009; 19:708.</a></li><li><a class="nounderline abstract_t">Torkildsen GL, Cockrum P, Meier E, et al. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Curr Med Res Opin 2011; 27:171.</a></li><li><a class="nounderline abstract_t">Lee H, Chung B, Kim KS, et al. Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial. Am J Ophthalmol 2014; 158:1172.</a></li><li><a class="nounderline abstract_t">Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther 2006; 22:47.</a></li><li><a class="nounderline abstract_t">Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006; 25:171.</a></li><li><a class="nounderline abstract_t">Prabhasawat P, Tesavibul N, Mahawong W. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea 2012; 31:1386.</a></li><li><a class="nounderline abstract_t">Sakassegawa-Naves FE, Ricci HMM, Moscovici BK, et al. Tacrolimus Ointment for Refractory Posterior Blepharitis. Curr Eye Res 2017; 42:1440.</a></li><li><a class="nounderline abstract_t">Holzchuh FG, Hida RY, Moscovici BK, et al. Clinical treatment of ocular Demodex folliculorum by systemic ivermectin. Am J Ophthalmol 2011; 151:1030.</a></li><li><a class="nounderline abstract_t">Kheirkhah A, Casas V, Li W, et al. Corneal manifestations of ocular demodex infestation. Am J Ophthalmol 2007; 143:743.</a></li><li class="breakAll">XDEMVY™ (lotilaner ophthalmic solution) 0.25%, for topical ophthalmic use. US Food and Drug Administration (FDA) approved product information. Revised July 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217603s000lbl.pdf (Accessed on July 28, 2023).</li><li><a class="nounderline abstract_t">Gaddie IB, Donnenfeld ED, Karpecki P, et al. Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2). Ophthalmology 2023; 130:1015.</a></li></ol></div><div id="topicVersionRevision">Topic 6915 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21450913" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The international workshop on meibomian gland dysfunction: executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8779082" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Meibomian gland dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7124880" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Histopathology of meibomian gland dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6218459" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Classification of chronic blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3156100" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Blepharitis associated with acne rosacea and seborrheic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8776558" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Meibomian gland triglyceride fatty acid differences in chronic blepharitis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3941038" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Analysis of the free fatty acid component of meibomian secretions in chronic blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12815527" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Polar lipids in human meibomian gland secretions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15502478" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Meibomianitis: polar lipid abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11587145" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The pathology of dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586480" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Chronic blepharitis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The etiology and treatment of blepharitis: a study in military personnel</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6743618" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparative bacteriology of chronic blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3466455" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bacterial aspects of chronic blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2019106" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lid flora in blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3957566" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bacterial lipases and chronic blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/126074" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The sebum excretion rate in rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19958291" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Impression cytology and ocular surface characteristics in patients with seborrhoeic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1460262" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15106913" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The lipid layer of tears: dependent on meibomian gland function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/420477" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Demodex folliculorum in hair follicles of eyelid skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16033750" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The Prevalence of Demodex folliculorum in blepharitis patients and the normal population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16033750" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The Prevalence of Demodex folliculorum in blepharitis patients and the normal population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3818198" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chronic blepharitis and dry eyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15774912" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Blepharokeratoconjunctivitis in children: diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17317407" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Long-term visual outcome of childhood blepharokeratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16123406" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : High prevalence of Demodex in eyelashes with cylindrical dandruff.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10633658" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Dry eye, blepharitis and chronic eye irritation: divide and conquer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/324453" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Staphylococcal blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3050690" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Inflammatory diseases of the peripheral cornea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23813417" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Objective image analysis of the meibomian gland area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26226467" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Evaluation of Optical Coherence Tomography Meibography in Patients With Obstructive Meibomian Gland Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26226477" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Noninvasive Imaging of Tear Film Dynamics in Eyes With Ocular Surface Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7422266" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Masquerade syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10336029" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ocular surface neoplasia masquerading as chronic blepharoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2658172" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sebaceous carcinoma of the ocular adnexa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15582067" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Sebaceous carcinoma of the eyelids: personal experience with 60 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22592706" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Interventions for chronic blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22592706" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Interventions for chronic blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26031204" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effects of Eyelid Warming Devices on Tear Film Parameters in Normal Subjects and Patients with Meibomian Gland Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26126722" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Temperature profiles of patient-applied eyelid warming therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3369982" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Experience with a new detergent lid scrub in the management of chronic blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8828939" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A comparative study of eyelid cleaning regimens in chronic blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19277245" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24039409" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21045648" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29652551" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25719253" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Oral omega-3 fatty acid treatment for dry eye in contact lens wearers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23642375" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Short-term consumption of oral omega-3 and dry eye syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27817918" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18781287" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22668581" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24357250" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect of azithromycin on lipid accumulation in immortalized human meibomian gland epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26707417" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Oral Antibiotics for Meibomian Gland-Related Ocular Surface Disease: A Report by the American Academy of Ophthalmology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12883348" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4953785" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cutaneous pharmacology of the tetracyclines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4697929" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Inhibition by tetracycline in the occurrence of extracellular lipase from Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1917401" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8328549" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy of doxycycline and tetracycline in ocular rosacea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19787586" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21138337" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25128594" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16503775" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371776" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23135530" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28922018" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Tacrolimus Ointment for Refractory Posterior Blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21334593" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical treatment of ocular Demodex folliculorum by systemic ivermectin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17376393" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Corneal manifestations of ocular demodex infestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17376393" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Corneal manifestations of ocular demodex infestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37285925" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2).</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
